Edition:
United Kingdom

People: ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

8.96USD
16 Aug 2019
Change (% chg)

$0.32 (+3.70%)
Prev Close
$8.64
Open
$8.66
Day's High
$8.99
Day's Low
$8.61
Volume
307,273
Avg. Vol
745,677
52-wk High
$12.21
52-wk Low
$2.23

Lindsay, Ronald 

Dr. Ronald M. Lindsay, Ph.D., is an Independent Director of the Company., since June 10, 2005. Dr. Lindsay has been a director since June 2005. He is currently Chairman and CEO of Zebra Biologics Inc., a privately held biopharmaceutical company. He was formerly EVP R&D and a director at Sequenom, Inc., and is currently a director of two privately-held companies, NeurocentRx Pharmaceuticals Ltd, Edinburgh and Depixus SAS, Paris. Dr. Lindsay was previously Chief Scientific Officer and Vice President, Research and Development, at diaDexus, Inc., and held a number of senior management positions at Millennium Pharmaceuticals, Inc., including SVP, Biotherapeutics. At Regeneron Pharmaceuticals, he was a founding scientist and led pre-clinical R&D from 1988?–?1998. Dr. Lindsay also worked at the Sandoz Institute for Medical Research, London. Dr. Lindsay completed post-doctoral work at the Friedrich Miescher Institute, Basel, and he holds a B.Sc. (Hons) in Chemistry from the University of Glasgow and a Ph.D. in Biochemistry from the University of Calgary. He is the author of over 150 peer reviewed publications in the field of neuroscience.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 106,188
Fiscal Year Total, USD 106,188

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Patrick Zenner

110,485

Peter Lawrence

1,168,540

Paolo Pucci

1,744,530

Marc Schegerin

--

Brian Schwartz

1,057,610

Timothy Barabe

92,438
As Of  31 Dec 2018